US FDA grants full approval for Pfizer's cervical cancer drug-April 2024-www.financetom.com

US FDA grants full approval for Pfizer's cervical cancer drug

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

US FDA grants full approval for Pfizer's cervical cancer drug

Apr 29, 2024 1:21 PM

April 29 (Reuters) - The U.S. Food and Drug

Administration granted traditional approval for Pfizer's ( PFE )

drug for cervical cancer patients with disease progression on or

after chemotherapy, the agency said on Monday.

(Reporting by Pratik Jain in Bengaluru; Editing by Anil

D'Silva)

Previous page： Britain takes aim at Apple and Google's dominance in smartphones Next page： Form 8.3 - Dowlais Group PLC

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Britain takes aim at Apple and Google's dominance in smartphones

Oct 22, 2025

LONDON, Oct 22 (Reuters) - Britain on Wednesday moved to loosen the grip of Apple ( AAPL ) and Google in smartphones by designating them as having strategic market status, giving it the power to demand specific changes to boost competition. The Competition and Markets Authority said Apple ( AAPL ) and Google's mobile platforms were used by businesses right...

Form 8.3 - Dowlais Group PLC

Oct 22, 2025

LONDON--(BUSINESS WIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of...

Form 8.3 - Qualcomm Incorporated

Oct 22, 2025

LONDON--(BUSINESS WIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Verition Fund Management LLC (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee...

Update: AT&T Shares Down After Q3 Adjusted Earnings Unchanged

Oct 22, 2025

09:42 AM EDT, 10/22/2025 (MT Newswires) -- (Updates with recent stock movement in the headline and first paragraph.) AT&T ( T ) shares were down nearly 3% in early Wednesday trading after the company reported Q3 adjusted earnings of $0.54 per diluted share, unchanged from a year earlier. Analysts polled by FactSet expected $0.54. Total operating revenue for the quarter...